Get all your news in one place.

100's of premium titles.
One app.

Start reading

Get all your news in one place.

100's of premium titles. One news app.

Start reading

Medical Daily

Health

Joseph James

'Rhino Tranq' Is in the Drug Supply and Naloxone Won't Stop It: A Growing Overdose Crisis Hiding in Plain Sight

CDC Chicago Opioids Public Health

A Growing Overdose Crisis Hiding in Plain Sight (Credit: Medical Daily)

When emergency medical teams respond to an overdose call, their most reliable tool has long been naloxone — a medication that rapidly reverses the effects of opioids and has saved hundreds of thousands of lives since the fentanyl crisis began. That tool is now losing its effectiveness against a new and rapidly spreading threat. A veterinary sedative known on the street as "rhino tranq" — scientifically called medetomidine — is increasingly being mixed into the illegal fentanyl supply, and unlike fentanyl, it does not respond to naloxone.

On April 2, 2026, the Centers for Disease Control and Prevention (CDC) and the White House Office of National Drug Control Policy (ONDCP) issued a joint Health Advisory warning clinicians, public health professionals, and the public about the escalating presence of medetomidine in illicit drug samples across the United States. The advisory represents one of the most significant updates to the overdose crisis landscape in years — and its implications for cities like Chicago, Philadelphia, and New York are deeply alarming.

The Numbers Tell a Disturbing Story

The scale of medetomidine's spread is difficult to overstate. According to the CDC's surveillance data, medetomidine was detected in 247 drug samples in 2023. By 2024, that number had climbed to 2,616. In 2025, it reached 8,233 — a more than 3,000% increase in just two years. Forensic analysis found that approximately 98% of medetomidine-positive samples also contained fentanyl, suggesting that dealers are deliberately combining the two substances, possibly to intensify the high or to stretch supply.

Between October 2025 and January 2026, wastewater surveillance programs detected medetomidine every single week in at least one of 14 states participating in the program. The highest concentrations are in the Northeast and Midwest — precisely the regions already hardest hit by the fentanyl epidemic.

Chicago: Ground Zero for the First Major Cluster

Chicago holds the grim distinction of being the site of the first major documented medetomidine overdose cluster in the United States. In May 2024, the Chicago Department of Public Health (CDPH) and the Illinois Department of Public Health were alerted to a dramatic spike in overdose responses on the city's West Side. In a single day — May 11, 2024 — emergency services recorded 50 overdose calls, more than double the 2023 daily average of 27.4. Subsequent investigation identified 12 confirmed, 26 probable, and 140 suspected medetomidine-involved overdoses from that cluster. At least 16 people were hospitalized. One person died. Prior to that event, medetomidine had never been detected in Chicago's drug supply.

That cluster was a warning shot. Two years later, medetomidine has been detected in at least 18 states and Washington, D.C., with surveillance data suggesting it is now displacing the previous adulterant of choice — xylazine — in many major markets. In Philadelphia, for example, xylazine was present in 97% of fentanyl samples in May 2024. By November of the same year, medetomidine had largely taken its place, appearing in 87% of fentanyl samples. Medetomidine has been detected in 46 overdose deaths in Philadelphia since May 2024 alone.

Why Rhino Tranq Is Particularly Dangerous

Medetomidine is classified as an alpha-2 adrenergic agonist — the same pharmacological category as xylazine and clonidine — but it is significantly more potent and longer-acting than either. It produces deep sedation, severe respiratory depression, and pronounced bradycardia (dangerously slow heart rate). Some patients in the Chicago cluster required atropine to restore normal cardiac rhythm.

The critical problem for emergency responders is that while naloxone will reverse the opioid component of a combined fentanyl-medetomidine overdose, it has no effect on medetomidine itself. A patient may partially revive after naloxone administration and then slip back into life-threatening sedation. The CDC advisory explicitly warns that clinicians should suspect medetomidine whenever a patient experiences prolonged sedation that does not fully respond to naloxone, and that such patients may require intensive supportive care beyond what standard overdose protocols provide.

Adding another layer of danger, stopping medetomidine after regular exposure triggers a severe withdrawal syndrome distinct from opioid withdrawal. Symptoms include severe hypertension, tachycardia, nausea, vomiting, anxiety, and fluctuating consciousness — a presentation that is likely to be misidentified in emergency settings not yet familiar with the drug.

A Drug War Policy Failure With Real Consequences

The emergence of medetomidine in the drug supply is, in part, a direct consequence of the fentanyl supply chain disruptions brought about by law enforcement pressure on xylazine — the previous adulterant. As regulatory and enforcement efforts target one substance, cartel chemists and distributors pivot to the next available option with comparable or superior effects. Medetomidine, used commercially as a sedative for large animals including rhinos and elephants (hence the street name "rhino tranq"), is far more accessible than many controlled substances and does not appear on standard clinical toxicology screens, making it invisible to most hospital drug tests.

Sara Carter, Director of the Office of National Drug Control Policy, stated in April 2026: "Medetomidine represents a real threat to communities, and this once again reaffirms that the only safe level of illegal drug use is zero." It is a correct assessment — but one that must be accompanied by real-world harm reduction strategies given that addiction treatment capacity in cities like Chicago remains dramatically insufficient relative to the scale of the crisis.

What Cities and Clinicians Must Do Now

The CDC advisory calls for expanded forensic drug testing to detect medetomidine at the local level, updated toxicology protocols in emergency departments, and public education campaigns targeting people who use drugs. The L.A. County Department of Public Health is already providing free fentanyl test strips through community health stations at schools, hotels, and churches. Chicago's overdose prevention infrastructure, which received a notable expansion when NYC Health Department extended its overdose prevention program to a 16th hospital in early 2026, must be similarly reinforced.

The bottom line: the overdose crisis has entered a new and more lethal phase. Municipalities, emergency services, and hospitals that are not actively updating their protocols for medetomidine-involved overdoses are operating on outdated assumptions — and people are dying because of it.